This comprehensive investor profile provides a detailed synthesis of the operational, strategic, and financial standing of **Adeshwar Meditex Limited (BSE SME: 543309)**. ### Corporate Identity and Operational Footprint Established in **1951** and incorporated in **2007**, Adeshwar Meditex Limited is an **ISO 13485:2016** certified manufacturer, exporter, and trader specializing in sterile surgical wound dressings and medical disposables. The company serves a diverse clientele across the healthcare, automobile, and defense sectors both in India and internationally. | Feature | Details | | :--- | :--- | | **Listing Status** | Listed on **BSE SME** platform since **June 28, 2021** | | **Manufacturing Facility** | 17-18, Dewan & Sons Udyog Nagar, **Palghar (West)**, Maharashtra | | **Registered Office** | Gala 111 Lok Centre, Marol Maroshi Road, Andheri East, Mumbai | | **Subsidiaries** | **None** (UAE subsidiary ceased operations in **Jan 2023**) | | **Accounting Standard** | Follows **AS 20** (Exempted from IND-AS) | --- ### Specialized Product Portfolio and Verticals The company operates through two primary verticals: **In-house Manufacturing** (Palghar facility) and **Trading/Marketing** (utilizing third-party manufacturers for specific pharmaceutical lines). * **Advanced Wound Care:** Includes sterile medicated dressings, tulle dressings, and high-tech hemostatic solutions such as **Chitosan**, **Oxidized Cellulose**, and **Gelatin Sponges**. * **Medical Disposables & PPE:** A comprehensive range of **PPE kits**, HIV kits, face masks, surgical gowns, shields, and gloves. * **Bandages & Orthopedics:** Elastic, adhesive, and non-adhesive bandages; specialized orthopedic soft products and equipment. * **Specialized Medical Kits:** * **Automobile & Industrial:** First aid kits tailored for vehicle manufacturers and factories. * **Public Health:** Home Based New Born (**HBNC**) kits and pre/post-operation medical kits. * **Pharmaceuticals & Hygiene:** Antiseptic solutions, hand sanitizers, medicated ointments, and alcohol-based products including **Extra Neutral Ethyl Alcohol**. * **Turnkey Solutions:** The company provides consultancy and supply for establishing medical product lines. --- ### Strategic Ownership Transition (2024) Following the demise of the previous promoter in 2023, the company underwent a formal change in management to address a leadership void and stabilize operations. * **The Acquisition:** In **August 2024**, **Mr. Krishnojirao Nagaraja Rao** and **Mr. Nagaraja Rao Abhinandan** assumed control via a Share Purchase Agreement (**SPA**) for **42.65%** of the equity and a subsequent **Open Offer** for **26%** at **₹20.72** per share. * **New Leadership Structure:** * **Chairperson & Whole-time Director:** Dr. Krishnojirao Nagaraja Rao * **Managing Director:** Mrs. Ashalata Raut * **Chief Financial Officer:** Mr. Prashant Rane * **Asset Commitment:** The new promoters have committed to **not alienating or disposing of** significant company assets for at least **two years** (until 2026) to ensure business continuity. --- ### Market Dynamics and Growth Catalysts Adeshwar Meditex is positioning itself to capture a larger share of the Indian healthcare market, which is projected to reach **USD 638 billion by FY25**. | Market Segment | Metric | Value / Projection | | :--- | :--- | :--- | | **India Wound Dressing Market** | Projected Value (FY25) | **USD 521.9 Million** | | **Advanced Wound Care CAGR** | Growth Rate (2023-2030) | **5.1% - 6.1%** | | **Global Wound Dressing Market** | Market Size (2023) | **USD 14.20 Billion** | **Key Strategic Drivers:** * **Demographic Shifts:** Rising prevalence of chronic wounds, diabetes, and a growing geriatric population. * **Infrastructure Expansion:** Increased demand for healthcare professionals and facilities, projected to double by **FY 2030**. * **Government Initiatives:** Leveraging schemes like **Ayushman Bharat** and **Jan Aushadhi** to increase penetration in Tier 2 and Tier 3 cities. * **R&D Focus:** Transitioning toward **Biosimilars**, **Complex Generics**, and **Novel Drug Delivery Systems** to maintain international quality standards. --- ### Financial Profile and Capital Structure The company is currently focused on strengthening its balance sheet and consolidating its financial status following the management change. * **Share Capital:** Authorized Capital of **₹15.00 Crore**; Paid-up Capital of **₹14.43 Crore** (**1,44,31,426** equity shares). * **Debt Management:** Significant reduction in long-term borrowings from **₹407.14 Lakhs** (2022) to **₹231.64 Lakhs** (2023). * **Collateral:** Loans are secured by the **30,753 sq. ft.** Palghar factory and Fixed Deposits totaling **₹167.92 Lakhs**. * **Dividend Policy:** The Board has recommended **no dividend** for the recent fiscal years, opting to retain earnings for internal growth and operational recovery. --- ### Risk Assessment and Mitigation Investors should note the following risks associated with the current transition phase: * **Public Shareholding Compliance:** Post-acquisition, the promoter group may hold up to **87.15%** of equity. The company must take action to return to the **25% Minimum Public Shareholding (MPS)** requirement, which may create volatility in the share price. * **Human Capital Constraints:** The business faces high dependency on manual labor and a shortage of skilled manpower. * *Mitigation:* The company is investing in **modernization and automation** to reduce labor dependency and ensure optimum capacity utilization. * **Operational Recovery:** Following a period of declining revenue and NPAT, the new management is tasked with a rapid turnaround. * **Regulatory Standing:** There are currently **no material orders** from regulators or courts impacting the company’s status as a **going concern**, and no directors are listed as **Wilful Defaulters**.